Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 29Myeloid 18Classical hematology 3Thoracic 2Lymphoid 2Dermatologic 2Sarcoma 1Other solid neoplasm 1NET 1Genitourinary 1Endocrine 1CNS 1Breast 1

Conditions

Neurofibrosarcoma 1

Interventions

Cyclophosphamide 55Specimen Handling 50Magnetic Resonance Spectroscopy 49Doxorubicin 44pembrolizumab 43Radiotherapy 42Temozolomide 38Biopsy 34Radiation 29Nivolumab 28fludarabine 23Vincristine 22Irinotecan 21Gemcitabine 21X-Rays 20Ifosfamide 20Surgical Procedures, Operative 19atezolizumab 17cabozantinib 15Ipilimumab 15olaparib 13Sunitinib 13Paclitaxel 13Etoposide 13Blood Specimen Collection 13regorafenib 12fludarabine phosphate 12Phantoms, Imaging 12Imatinib Mesylate 12liposomal doxorubicin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
decitabine and cedazuridine drug combination × Sarcoma × 1 year × Clear all
NCT04872543 2026-02-05

A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
25 enrolled
Sarcoma

Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡